# Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

> **NCT03976843** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 175 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 18F-DCFPyL

## Key facts

- **NCT ID:** NCT03976843
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-04
- **Primary completion:** 2027-11-19
- **Final completion:** 2027-11-19
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03976843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03976843, "Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03976843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*